下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
02005 石四药集团
3.6100.0000.00%
显示同比
不显示
隐藏空行
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
-- -- 40.03% 0.2321 -- -- 8.89% 0.0395
Cash Flow Per Share
-- -- -68.13% 0.0585 -- -- -150.83% -0.0516
Operating Income Per Share
42.42% 0.5792 27.69% 1.7876 -- 1.2961 37.22% 0.8072
Net Asset Per Share
-- -- 11.76% 2.0752 -- -- 18.94% 1.9305
Basic Earning Per Share
-- -- 28.73% 0.2599 -- -- 11.66% 0.091
Diluted  Earning Per Share
-- -- 28.78% 0.2591 -- -- 11.84% 0.0907
Profitability
Gross Profit Ratio
-8.03% 58.800% -6.89% 59.182% -- 59.791% -6.01% 60.165%
Operating Profit Ratio
-8.03% 58.800% 3.57% 18.446% -- 59.791% -14.65% 14.718%
Net Profit Ratio
-8.03% 58.800% 2.65% 14.716% -- 59.791% -18.08% 11.382%
Earning Before Tax Ratio
-8.03% 58.800% 4.02% 17.705% -- 59.791% -15.08% 13.877%
ROE
-- -- 15.03% 13.235% -- -- -3.83% 4.797%
ROA
-- -- 9.17% 7.870% -- -- -6.91% 2.930%
Yield Quality
Operating Profit To Total Profits
0% 100.000% -0.44% 104.185% -- 100.000% 0.51% 106.067%
Tax To Total Profits
-- -- 7.02% 16.882% -- -- 20.05% 17.979%
Operating Cash To Total Revenue
-- -- 9.66% 12.986% -- -- -20.65% 4.893%
Capital Structure
Debt Assets Ratio
-- -- 9.13% 39.370% -- -- 0.84% 36.145%
Equity Multipler
-- -- 5.18% 1.722 -- -- 0.99% 1.6373
Debt Equity Ratio
-- -- 15.05% 64.935% -- -- 1.32% 56.605%
Current Assets To tatal Assets
-- -- -0.9% 45.607% -- -- 2.16% 46.633%
Non Current Assets To Total Assets
-- -- 0.77% 54.393% -- -- -1.82% 53.367%
Current Liabilities To tatal Liabilities
-- -- -10.47% 56.792% -- -- -2.71% 57.882%
Non Current Liabilities To Total Liabilities
-- -- 18.16% 43.208% -- -- 3.99% 42.118%
Solvency
Current Ratio
-- -- 1.43% 2.0398 -- -- 4.14% 2.2289
Quick Ratio
-- -- -0.9% 1.6942 -- -- 3.94% 1.8557
Operating Profit To Current Liabilities
-- -- 15.16% 0.4127 -- -- -0.6% 0.1797
Operrating Cash Flow To Current Liabilities
-- -- 21.94% 0.2905 -- -- -7.59% 0.0597
Share Equity Without Minority Interest To Total Liabilities
-- -- -12.87% 1.4751 -- -- -1.8% 1.6898
Operating Cash Flow To Total Liabilities
-- -- 9.17% 0.165 -- -- -10.1% 0.0346
Operating Profit To Total Liabilities
-- -- 3.1% 0.2344 -- -- -3.3% 0.104
Operating Capacity
Inventory Turnover(T)
-- -- 10.03% 2.9834 -- -- 21.61% 1.405
Current Assets Turnover(T)
-- -- 4.83% 1.1718 -- -- 10.09% 0.5603
Fixed Assets Turnover(T)
-- -- 15.57% 1.3584 -- -- 18.83% 0.6304
Total Assets Turnover(T)
-- -- 6.92% 0.5367 -- -- 14.31% 0.2596
Growth Ability
Operating Revenue GR 3Y
-- -- -26.95% 28.128% -- -- -51.55% 16.725%
Gross Income GR 3Y
-- -- -56.62% 21.634% -- -- -80.04% 11.324%
Operating Profit GR 3Y
-- -- -3.72% -11.260% -- -- -88.29% -34.043%
EBT GR 3Y
-- -- -33.88% -12.116% -- -- -100.24% -35.196%
Net Profit GR 3Y
-- -- -73.27% -13.812% -- -- -170.84% -37.758%
Net Profit Attributable To The Parent Company GR 3Y
-- -- -74.48% -13.846% -- -- -167.98% -38.129%
Total Assets GR 3Y
-- -- -1.95% 55.633% -- -- 3.3% 58.310%
Share Equity Without Minority Interest GR 3Y
-- -- -25.4% 46.726% -- -- -33.26% 43.474%
Equity GR 3Y
-- -- -30.66% 48.295% -- -- -35.68% 45.867%
Total Liabilities GR 3Y
-- -- 79.65% 68.472% -- -- 143.92% 86.402%
Basic Earning Per Share GR 3Y
-- -- -7.44% -14.619% -- -- -99.8% -39.212%
Net Assets Per Share GR 3Y
-- -- -10.97% 47.574% -- -- -21.64% 42.902%
Other Indicators
Currency Unit
港元港元港元港元

Q6、Q9、FY为累计季报:Q6 为中期报告;Q9 为第三季报;FY为年报。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
石四药集团有限公司,前称为利君国际医药(控股)有限公司,是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药,包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。
董事长: 曲继广
所属市场: 香港主板
上市日期: 2005/12/20
富途热股榜
港股美股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部